MLTX

MKT CAP:$1B

MoonLake Immunotherapeutics

Market Cap

$1B

Healthcare·Biotechnology·🇨🇭 Switzerland·NASDAQ

Healthcare·Biotechnology·🇨🇭·NASDAQ

Stock Price

$17.22+$5.27 (+44.10%)

Apr 22, 2026

Company Details

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in c...

CEO

Jorge Santos da Silva

IPO Date

Oct 20, 2020

Website

www.moonlaketx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$81M

EPS (Diluted)

-$1.76

Free Cash Flow

-$110M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2025

May 11, 2026

PENDING

Q4 2024

Feb 26, 2025

$0EPS -$0.72

Q4 2023

May 7, 2024

$0EPS -$0.12

FY 2022

Mar 20, 2023

$0EPS -$2.20

Q2 2022

Aug 12, 2022

$0EPS -$0.49

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$0	$0	-$100.8K
Q1 21	$0	$0	-$94.1K
Q2 21	$0	$0	-$33M
Q3 21	$0	$0	-$6M
Q4 21	$0	-$2.5K	-$14M
Q1 22	$0	$0	-$16M
Q2 22	$0	$0	-$18M
Q4 23	$0	$0	-$15M
Q4 24	$0	$0	-$50M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$107.8K	-$107.8K
Q2 21	$6.1K	$6.1K
Q3 21	-$2M	-$2M
Q4 21	-$7M	-$7M
Q1 22	-$14M	-$14M
Q2 22	-$34M	-$34M
Q4 23	-$12M	-$13M
Q4 24	-$48M	-$49M

Capital Expenditures

Quarter	CapEx
Q1 21	$0
Q2 21	$0
Q3 21	$11.6K
Q4 21	$18.4K
Q1 22	$16.0K
Q2 22	$16.0K
Q4 23	$284.6K
Q4 24	$175.6K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+14070.4%
Q1 22	—	+16840.8%
Q2 22	—	-46.0%
Q4 23	—	+139.8%
Q4 24	—	+247.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$0	—
Q2 21	$1M	—
Q3 21	$2M	—
Q4 21	$0	—
Q1 22	$2M	—
Q2 22	$0	—
Q4 23	$2M	—
Q4 24	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 20	—	—	$100.8K
Q1 21	—	—	$94.1K
Q2 21	$30M	$3M	—
Q3 21	$669.5K	$6M	—
Q4 21	$5M	—	$9M
Q1 22	$10M	$5M	—
Q2 22	$11M	$6M	—
Q4 23	$8M	$7M	—
Q4 24	$40M	$9M	—

Revenue Segments

Quarter	License
Q2 22	$302M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$101M	$0	$101M
Q2 22	$93M	$0	$93M
Q3 22	$41M	$42M	$83M
Q4 22	$40M	$33M	$72M
Q1 23	$50M	$13M	$63M
Q2 23	$502M	$0	$502M
Q3 23	$318M	$178M	$496M
Q4 23	$451M	$60M	$511M
Q1 24	$458M	$89M	$547M
Q2 24	$343M	$177M	$520M
Q3 24	$376M	$118M	$494M
Q4 24	$180M	$268M	$448M
Q1 25	$272M	$209M	$480M
Q2 25	$307M	$118M	$425M
Q3 25	$351M	$30M	$380M
Q4 25	$335M	$59M	$394M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	15M	—	—
Q1 21	15M	0.0%	—
Q2 21	37M	+149.4%	—
Q3 21	37M	0.0%	—
Q4 21	37M	0.0%	+149.4%
Q1 22	37M	0.0%	+149.4%
Q2 22	35M	-4.7%	-4.7%
Q4 23	60M	+70.2%	+62.3%
Q4 24	63M	+5.3%	+70.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	$0	2
Q1 21	$0	2
Q2 21	$0	2
Q3 21	$0	2
Q4 21	$0	2
Q1 22	$0	2
Q2 22	$0	2
Q4 23	$0	50
Q4 24	$0	100

Revenue / Employee